An open-label randomized phase III study of intermittent oral Capecitabine in combination with intravenous Oxaliplatin (Q3W) ("XELOX") versus Fluorouacil/Leucovorin as adjuvant therapy for patients
Projektleiter:
Finanzierung:
Industrie;
Prof. Schmoll: An open-label randomized phase III study of intermittent oral Capecitabine in combination with intravenous Oxaliplatin (Q3W) ("XELOX") versus Fluorouacil/Leucovorin as adjuvant therapy for patients who have undergone surgery for colon carcinoma, UICC/AJCC stage III (Dukes stage C)
Kontakt
Prof. Dr. Hans-Joachim Schmoll
Martin-Luther-Universität Halle-Wittenberg
Universitätsklinik und Poliklinik für Innere Medizin IV
Ernst-Grube-Str. 40
06120
Halle (Saale)
Tel.:+49 345 5572606
weitere Projekte
Die Daten werden geladen ...